Compare ESOA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | ABOS |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.4M | 197.9M |
| IPO Year | 2006 | 2021 |
| Metric | ESOA | ABOS |
|---|---|---|
| Price | $11.79 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $21.00 | $8.00 |
| AVG Volume (30 Days) | 162.8K | ★ 332.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $122,465,826.00 | N/A |
| Revenue This Year | $9.22 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $32.66 | ★ N/A |
| Revenue Growth | ★ 2.74 | N/A |
| 52 Week Low | $7.84 | $1.21 |
| 52 Week High | $19.94 | $3.60 |
| Indicator | ESOA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 63.34 |
| Support Level | $7.94 | $2.13 |
| Resistance Level | $15.92 | $3.34 |
| Average True Range (ATR) | 0.45 | 0.18 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 13.22 | 61.81 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.